Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GILDESS FE 1.5/30 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive: ethinyl estradiol (estrogen) and levonorgestrel (progestin) suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Ethinyl estradiol: terminal elimination half-life approximately 13-27 hours (mean ~17 hours); clinical context: supports daily dosing with steady state achieved in ~1 week. Gestodene: terminal elimination half-life approximately 12-15 hours; clinical context: allows for maintaining stable serum concentrations with once-daily dosing.
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes conjugation (glucuronidation and sulfation). Levonorgestrel: metabolized by reduction and conjugation; CYP3A4 involved.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Ethinyl estradiol (EE) is primarily excreted in urine (40-45%) and feces (40-45%) as glucuronide and sulfate conjugates; less than 8% is excreted unchanged. Gestodene is extensively metabolized; its metabolites are excreted in urine (50-60%) and feces (30-40%), with less than 1% unchanged.
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Ethinyl estradiol: 97-98% bound to albumin; gestodene: 65-75% bound to sex hormone-binding globulin (SHBG) and 25-35% bound to albumin; total binding ~99%.
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Ethinyl estradiol: apparent Vd ~2.5-4.0 L/kg (mean ~3 L/kg); indicates extensive tissue distribution beyond plasma volume. Gestodene: apparent Vd ~0.7-1.0 L/kg; suggests moderate distribution to tissues.
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Ethinyl estradiol: oral bioavailability approximately 40-45% due to first-pass metabolism (sulfation and glucuronidation in gut wall and liver); interindividual variability significant. Gestodene: oral bioavailability nearly 100% (99-100%) due to minimal first-pass metabolism; high and consistent absorption.
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to potential estrogen-related fluid retention and hypertension.
No data available for fictional drug ALYACEN 777.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; closely monitor liver function.
No data available for fictional drug ALYACEN 777.
Not indicated for use before menarche. Post-menarche: same as adult dosing; one tablet orally once daily.
No data available for fictional drug ALYACEN 777.
Not indicated for use in postmenopausal women due to lack of efficacy for contraception and potential increased thromboembolic risk.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially >35 years) and number of cigarettes smoked. Women >35 years who smoke should not use this product.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thrombotic disorders (venous thromboembolism, arterial thromboembolism, stroke, myocardial infarction),Carcinoma of the breast and reproductive organs,Hepatic neoplasia,Gallbladder disease,Carbohydrate and lipid metabolism effects,Elevated blood pressure,Headache,Bleeding irregularities,Ocular lesions (e.g., retinal thrombosis),Depression
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy,Benign or malignant liver tumor,Hepatic impairment,Hypersensitivity to components,Women >35 years who smoke
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No significant food interactions. Grapefruit juice may slightly increase ethinyl estradiol levels but not clinically relevant. The iron component may cause gastrointestinal discomfort; taking with food can reduce this, but avoid taking with dairy (calcium) or caffeine as they may reduce iron absorption. Iron tablets should be taken with water or vitamin C source to enhance absorption, but not with tea, coffee, or milk.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
Pregnancy category X. Use contraindicated in pregnancy due to estrogenic effects on fetal development. First trimester: increased risk of congenital anomalies (cardiovascular, limb defects). Second and third trimesters: potential for fetal harm, including jaundice and liver dysfunction.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Contraindicated in breastfeeding. Estrogen and progestin components reduce milk production and quality. Limited data; M/P ratio not established. Alternative contraception recommended.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No dose adjustment due to contraindication in pregnancy. Pharmacokinetic changes in pregnancy (increased clearance) are not applicable as drug is not used.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
GILDESS FE 1.5/30 is a combination oral contraceptive containing ethinyl estradiol 30 mcg and gestodene 1.5 mg. Gestodene is a third-generation progestin with high progestational activity and minimal androgenic effects. The iron component (ferrous fumarate) is included to counteract menstrual blood loss. This formulation is associated with a lower risk of venous thromboembolism compared to second-generation pills but still carries a risk, particularly in smokers over 35. It should be taken at the same time daily to maintain efficacy. Breakthrough bleeding is common in the first few cycles; if persistent, rule out other causes. The iron tablets are not for contraceptive use and should be taken daily during the placebo week.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet daily at the same time, preferably after an evening meal to minimize nausea.,If you miss a dose, follow the package instructions: if missed by less than 12 hours, take it immediately; if more than 12 hours, take the last missed pill and use backup contraception for 7 days.,Use additional barrier contraception for the first 7 days of starting the pill, or if starting after day 5 of cycle, for the first cycle.,Smoking increases the risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience symptoms of a blood clot: sudden leg pain/swelling, chest pain, shortness of breath, or sudden severe headache.,The iron tablets are not for contraception; they help replace iron lost during menstruation.,Do not use this medication if you are pregnant, have a history of blood clots, certain migraines, liver disease, or hormone-sensitive cancer.,Antibiotics (except rifampin) generally do not affect efficacy, but always consult your doctor if you are prescribed any new medication.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GILDESS FE 1.5/30 vs ALYACEN 777, answered by our medical review team.
GILDESS FE 1.5/30 is a Oral Contraceptive that works by Combination oral contraceptive: ethinyl estradiol (estrogen) and levonorgestrel (progestin) suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GILDESS FE 1.5/30 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GILDESS FE 1.5/30 is: One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GILDESS FE 1.5/30 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GILDESS FE 1.5/30 is classified as Category C. Pregnancy category X. Use contraindicated in pregnancy due to estrogenic effects on fetal development. First trimester: increased risk of congenital anomalies (cardiovascular, limb. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.